Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listRanibizumab

Ranibizumab

Ranibizumab Structural

What is Ranibizumab?

Description

Ranibizumab is a recombinant, humanized, IgG1 monoclonal antibody fragment (Fab) that neutralizes all active forms of vascular endothelial growth factor A (VEGF-A), and it is indicated for the treatment of neovascular age-related macular degeneration (AMD). It consists of a nonbinding human sequence and a high-affinity binding epitope (Fab fragment) derived from the mouse. The full-length RhuMab VEGF (bevacizumab) was launched previously by Genentech for the treatment of colorectal cancer. Both the antibody fragment and the full-length antibody bind to and inhibit all active forms of VEGF-A and are derived from the same mouse monoclonal antibody. However, ranibizumab has been genetically engineered through a process of selective mutation to increase its affinity for binding and inhibiting the growth factor.

Originator

Genentech (US)

The Uses of Ranibizumab

Ranibizumab, a humanized antigen binding portion of a murine anti- VEGF monoclonal antibody with a mature high affinity for all VEGF isoforms, has been approved as an intravitreal treatment for neovascular AMD and is the first such treatment to improve visual acuity (VA) in neovascular AMD.
CRUISE is multicenter, randomized, double-masked, sham injectioncontrolled Phase III study of 392 participants designed to assess the efficiency and safety profile of ranimizumab for macular edema associated to CRVO. The month 6 result showed that 46.2% (61/132) of patients received 0.3 mg of ranimizumab and 47.7% (62/130) received 0.5 mg of ranimizumab had their vision improved by 15 letters or more compared to 16.9% (22/130) of patients receiving sham injections and mean gain was observed beginning at day seven with an 8.8 and 9.3 letter gain in the 0.3 mg and 0.5 mg study arms of ranimizumab, respectively, compared with 1.1 letters in the sham injection arm.

The Uses of Ranibizumab

antiangiogenic monoclonal antibody macular degeneration therapy

brand name

Lucentis

Properties of Ranibizumab

form  Liquid
color  Colorless to light yellow
CAS DataBase Reference 347396-82-1

Safety information for Ranibizumab

Computed Descriptors for Ranibizumab

Related products of tetrahydrofuran

You may like

  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 88491-46-7 98%
    88491-46-7 98%
    88491-46-7
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.